What is it about?
The lack of effective and safe analgesics for chronic pain management has been a health problem associated with people’s livelihoods for many years. Programmed cell death protein 1 (PD-1) is widely expressed in neurons and participates in the modulation of neuronal excitability, synaptic transmission, and synaptic plasticity. In this work, we screened an analgesic peptide H-20, which significantly inhibits acute pain and chronic pain via the PD-1 pathway with few adverse effects in multiple preclinical pain models.
Featured Image
Photo by ilgmyzin on Unsplash
Why is it important?
Our findings show that analgesic peptide H-20 is a promising candidate analgesic drug. Furthermore, our work confirms that developing a new analgesic therapy using PD-1 signaling to therapeutically alleviate chronic pain is feasible and worthy of future research.
Perspectives
Our group has been working to search for therapeutic targets and analgesic peptides in the treatment of chronic pain. We believe that PD-1 is an ideal analgesic target. We expect that this work will provide new ideas for analgesic drug research and development.
Gang Chen
Read the Original
This page is a summary of: An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects, Proceedings of the National Academy of Sciences, July 2022, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2204114119.
You can read the full text:
Contributors
The following have contributed to this page
